HC Wainwright Lifts Earnings Estimates for Beam Therapeutics

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at HC Wainwright upped their FY2026 earnings estimates for Beam Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($4.65) for the year, up from their previous forecast of ($4.67). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.66) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2026 earnings at ($1.27) EPS, Q1 2027 earnings at ($1.23) EPS, Q2 2027 earnings at ($1.26) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($5.09) EPS, FY2028 earnings at ($4.28) EPS, FY2029 earnings at ($2.95) EPS and FY2030 earnings at ($1.40) EPS.

Several other research firms have also recently issued reports on BEAM. Wedbush lifted their price objective on Beam Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. Guggenheim decreased their target price on Beam Therapeutics from $55.00 to $51.00 and set a “buy” rating on the stock in a research report on Thursday, November 5th. Wall Street Zen downgraded Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. Finally, Canaccord Genuity Group lowered their price target on Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Beam Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $47.36.

Beam Therapeutics Price Performance

Shares of Beam Therapeutics stock opened at $27.02 on Tuesday. Beam Therapeutics has a twelve month low of $20.23 and a twelve month high of $38.26. The firm’s 50-day moving average price is $25.53 and its 200 day moving average price is $28.00. The company has a quick ratio of 14.57, a current ratio of 13.01 and a debt-to-equity ratio of 0.11.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, November 3rd. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.11). Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $8.75 million. During the same period in the prior year, the firm earned ($1.10) EPS. The firm’s revenue for the quarter was down 96.8% on a year-over-year basis.

Insider Activity at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the sale, the chief executive officer directly owned 1,047,205 shares in the company, valued at $24,682,621.85. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc raised its holdings in Beam Therapeutics by 123.6% in the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock valued at $30,000 after acquiring an additional 685 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Beam Therapeutics in the 2nd quarter worth approximately $43,000. Hollencrest Capital Management purchased a new position in Beam Therapeutics in the 1st quarter worth approximately $43,000. Fulcrum Asset Management LLP acquired a new position in shares of Beam Therapeutics during the 3rd quarter worth approximately $51,000. Finally, Nykredit A S acquired a new position in shares of Beam Therapeutics during the 2nd quarter worth approximately $75,000. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: HC Wainwright increased its estimates for Q4 2026 and FY2026, and lifted forecasts for each quarter of 2027 and FY2027. It also raised its FY2028–FY2030 estimates; for example, the FY2030 loss forecast improved to $1.40 per share from $1.48. The company is still expected to report losses, including a projected $5.09 per-share loss in FY2027, but the revised figures are less negative than before.

About Beam Therapeutics

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development.

The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.